ReviewOncology reports2020
Circular RNAs: Novel biomarkers for cervical, ovarian and endometrial cancer (Review).
Review in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Advances in Nanotechnology in the Diagnosis and Treatment of Gynecological Cancers.International journal of nanomedicine · 2025Pooled it
- Circular RNAs in cervical cancer: from ceRNA networks to epitranscriptomic regulation, immune modulation, and metastatic reprogramming.Frontiers in immunology · 2026Review
- Exploring the role of circular RNAs in endometrial cancer progression and chemoresistance: Implications for targeted therapies.European journal of medical research · 2025Review
- Circular RNAs in gynecological cancer: From molecular mechanisms to clinical applications (Review).Oncology letters · 2025Review
- Present progress in biomarker discovery of endometrial cancer by multi-omics approaches.Clinical proteomics · 2025Review
- Exploration of the shared pathways and common biomarkers in cervical and ovarian cancer using integrated bioinformatics analysis.Discover oncology · 2024Article
- circRNAs in Endometrial Cancer-A Promising Biomarker: State of the Art.International journal of molecular sciences · 2024Review
- Serum hsa_circ_0007534 as a diagnostic biomarker for ovarian cancer.American journal of translational research · 2024Article
- Prediction of Chemoresistance-How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023Review
- circANKRD17(has_circ_0007883) confers paclitaxel resistance of ovarian cancer via interacting with FUS to stabilize FOXR2.Molecular and cellular biochemistry · 2023Article
- The roles and mechanisms of circular RNAs related to mTOR in cancers.Journal of clinical laboratory analysis · 2022Review
- Circular RNAs in endometrial carcinoma (Review).Oncology reports · 2022Review
- Gene Therapy for Malignant and Benign Gynaecological Disorders: A Systematic Review of an Emerging Success Story.Cancers · 2022Review
- Plasma circRNA microarray profiling identifies novel circRNA biomarkers for the diagnosis of ovarian cancer.Journal of ovarian research · 2022Article
- Oxymatrine induces anti-tumor response in cervical cancer by modulating circ_0008460/miR-197-3p/ribonucleotide reductase subunit M2 (RRM2).Bioengineered · 2022Article
- Circular RNA hsa_circ_0011324 is involved in endometrial cancer progression and the evolution of its mechanism.Bioengineered · 2022Article
- Circular RNA circ_0004488 Increases Cervical Cancer Paclitaxel Resistance via the miR-136/MEX3C Signaling Pathway.Journal of oncology · 2022Article
- CircSMARCA5: A key circular RNA in various human diseases.Frontiers in genetics · 2022Review
- Oncogenic circular RNA circ_0007534 contributes to paclitaxel resistance in endometrial cancer by sponging miR-625 and promoting ZEB2 expression.Frontiers in oncology · 2022Article
- The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical, ovarian and endometrial cancer are the three most common types of malignant tumor and the leading causes of cancer‑associated death in women. Tumor debulking surgery followed by platinum and paclitaxel chemotherapy is the current treatment regime of choice. However, as a result of late diagnosis and chemoresistance, the survival rates of patients with advanced gynecological cancers remains unsatisfactory. Circular RNAs (circRNAs) are stable noncoding RNAs that are present in a wide variety of tissue and cell types. With the enhancement of RNA sequencing methods, increasing numbers of circRNAs have been identified, and their functions are gradually being revealed. In recent years, circRNAs have received increasing attention for their regulatory roles in cervical, ovarian and endometrial cancer. The aim of the present review was to summarize the possible mechanisms of recently identified circRNAs; we hypothesize that a novel diagnostic and therapeutic biomarker may be identified to prolong the survival time of patients with gynecological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.